March 16, 2011 ·
Leave a comment
March 16, 2011 (CHAPEL HILL, NC)—Research Triangle, NC research and consulting firm Thought Leader Select has initiated a new assessment of medical experts in the field of oncology for the biopharmaceutical industry.
A Canadian subsidiary of a top 10 global biopharmaceutical company has hired the firm to study the skills and experiences of 40 key opinion leaders in the treatment of lung cancer. Thought Leader Select is offering the client company an objective, systematic foundational approach to selecting physicians and other health care professionals within the Canadian care environment to assist the company during its stretch-run of activities in support of the new cancer treatment’s development.
The selected key opinion leaders in Canadian oncology circles will provide a variety of services to the company, including advisory board participation, conducting clinical studies, and offering one-on-one consultations with the company’s scientific and medical teams. Thought Leader Select’s methodology, while compliant with Office of Inspector General guidelines in the United States, is also compliant with Canadian regulations such as the Personal Information Protection and Electronic Documents Act (PIPEDA).
“We have been privileged to work with this company on multiple projects in several therapeutic areas, to ensure that its new product teams are positioned for success by working with the right thought leaders for the right reasons,” stated Neil Mellor, Thought Leader Select’s business development consultant. “This ... read more »
February 14, 2011 ·
Leave a comment
February 14, 2011 (CHAPEL HILL, NC)—Thought Leader Select, a Research Triangle, NC firm focused on collaborations between the biopharmaceutical industry and the medical community, announces the launch of a new media partnership with biopharmaceutical industry blog Marketing4Health.
The research and consulting firm (Thought Leader Select) has signed on to become the blog’s exclusive sponsor, beginning February 14, 2011. With a growing international following and strong readership bases in the United States, Canada, and Europe, Marketing4Health focuses on healthcare and pharmaceutical marketing practices and challenges, as well as emerging trends in technology and social media. Natalie Bourre, the editor of Marketing4Health, is a 13-year industry veteran, with leadership positions at Alcon, Serono, and, most recently at Solvay, where she led the marketing team for Pantoloc (Protonix), which became the 5th largest Rx brand in Canada during her tenure.
“When we were seeking a media partner for 2011, the choice was obvious,” stated Brian Castle, the firm’s director of global marketing and client relations. “Natalie Bourre and Marketing4Health represent a perfect fit for our company, in that she is committed to advising the industry to market new medications in the right ways, whether to medical experts or consumers. With any advertising partnership, we want to drive potential clients our way, and we know that Natalie’s readers are our kind of people—leaders in the industry ... read more »
December 16, 2010 ·
In the Field with Neil: Observations from Neil Mellor, Business Development Consultant
“When the US sneezes,” as they say, “Canada catches a cold.” This cliché could not be more apt for the Canada pharmaceutical executive when it comes to managing relationships with key opinion leaders (KOLs). Canada is still a long way off from having similar regulatory activity to the US, with regard to governing interaction with healthcare professionals, but Canadians should pay attention to what is happening south of the border.
The Office of the Inspector General (OIG) is a well-known entity to any US pharmaceutical sales representative, product manager, sales or marketing executive. The OIG is a division of the US Department of Health and Human Services and has strict powers governing how the US pharmaceutical industry engages with KOLs and promotes pharmaceutical products. According to The OIG’s website (http://oig.hhs.gov/), “The OIG’s duties are carried out through a nationwide network of audits, investigations, inspections and other mission-related functions performed by OIG components.” The OIG has sweeping powers to investigate, prosecute and fine, if necessary, or even invoke jail terms. Since 2000, over $11.7 billion in legal settlements have been collected by the OIG from pharma companies promoting off-label usage of their products or violating the agency’s expectations of how the industry should interact with KOLs.
Canada ... read more »
July 23, 2010 ·
Leave a comment
Press Release Out Today from the Offices of Thought Leader Select
July 22, 2010 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina company dedicated to delivering sophisticated key opinion leader research solutions to the biopharmaceutical industry, announces new key opinion leader research for an established Mexican pharmaceutical company.
The pharmaceutical company, a long-time presence in the Mexican market, has contracted the firm for key opinion leader identification, profiling, and engagement strategies in support of a novel prescription medication for the relief of muscle and joint pain. Thought Leader Select will assess the skills and experiences of a host of rheumatologists and orthopedic surgeons throughout Mexico. The pharmaceutical firm will engage the identified medical experts for one-on-one consultations, advisory boards, and speaking engagements, as well as potential clinical studies for new treatment indications for the drug.
In addition to profiles and activity plans for the leading Mexican physicians, Thought Leader Select will also deliver access to its exclusive web-based expert tool for optimizing physician teams for a variety of development activities.
“Our customized services, well-known throughout the United States and Canada, work for companies operating domestically in Mexico as well as multi-nationals doing business throughout Latin America,” stated Dr. Daniel Bagi, head of Latin American business development at Thought Leader Select, from his office in Mexico City. “The launch of this project establishes Thought Leader ... read more »
July 8, 2010 ·
Leave a comment
In a recent study commissioned by a global pharmaceutical and medical device company, Thought Leader Select delivered an objective research assessment of the top 35 medical centers of excellence for the treatment of attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) across the United States and Canada. For the assessment, Thought Leader Select analyzed information in several key areas, including basic and clinical research, publications, residency programs, and treatment guidelines involvement.
Within the scope of the overall assessment, the client company commissioned a more focused look at the top centers of excellence for research in the ADD/ADHD field. The top center’s profile included 11 ongoing clinical trials to evaluate the potential for new medicines to effectively treat ADD and ADHD. Previously, the center completed nine major studies evaluating the effectiveness of various treatment methods for the conditions, and the center had generated 18 clinical trial publications over a seven-year period.
In addition to the center’s array of landmark studies and clinical trial participation, the Thought Leader Select assessment also noted the center’s dominance in the area of publishing. For this category, the company used keywords relevant to the client’s focus within the therapeutic area to determine medical journal article relevancy. The center had generated a total of 94 publications in the treatment area of ADD/ADHD since 2001, with 67 of ... read more »